新型冠状病毒肺炎药物治疗的研究进展

2019年12月,中国以湖北省武汉市为中心暴发了一场新型冠状病毒导致的肺炎疫情,称为新型冠状病毒肺炎(coronavirus disease 2019,COVID-19)疫情。截至2020年3月1日24时,据我国31个省(自治区、直辖市)和新疆生产建设兵团报告,累计确诊病例80026例,中国港澳台地区确诊148例。目前,COVID-19无特效抗病毒药物或疫苗,治疗药物的选择主要是基于既往严重急性呼吸综合征、中东呼吸综合征及其他一些流感病毒的治疗经验。瑞德西韦、氯喹、法匹拉韦、恢复期血浆在临床上初见疗效,但其安全性和疗效,还须要大样本量进一步验证。利巴韦林、洛匹那韦/利托那韦、干扰素-α、阿比多尔联合应用,应注意其不良反应,慎重选择。达鲁那韦目前还停留在体外实验阶段,中医辩证治疗还须进一步验证。本文围绕目前临床上治疗COVID-19药物的研究进展进行综述,为COVID-19治疗提供参考。

Advances in medication of COVID-19

In December 2019,novel coronavirus caused pneumonia outbroke in Wuhan,Hubei Province,China.It was named coronavirus disease 2019(COVID-19).Up to 24:00 March 1,2020,according to reports from 31 provinces(autonomous regions,municipalities)and the Xinjiang Production and Construction Corps,there have been a total of 80026 confirmed cases in China's Mainland and 148 confirmed cases in Hong Kong,Macao,and Taiwan regions of China.Currently,there are still no targeted specific antiviral drugs or vaccines for COVID-19.The drugs are selected mainly based on the previous treatment experience,such as severe acute respiratory syndrome,Middle East respiratory syndrome and some other influenza virus.Remdesivir,chloroquine,favipiravir,and convalescent plasma are clinically effective.However their safety and efficacy require further verifications in large sample size.For combined application of ribavirin,lopinavir/ritonavir,interferon-α and arbidol,more attentions should be paid to adverse reactions and the combination should be selected with caution.Darunavir is currently in vitro experiments,and TCM dialectical treatment should be further verified.This article reviews the current clinical research progress on the medication of COVID-19,so as to provide evidence for COVID-19 treatment.